Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/8/2015 |
| Start Date: | January 2013 |
| End Date: | December 2015 |
| Contact: | John M Levenick, MD |
| Email: | john.m.levenick@hitchcock.org |
| Phone: | 6036508150 |
The purpose of this study is to assess whether peri-procedural administration of rectal
indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
Inclusion Criteria:
1. Scheduled for an ERCP at Dartmouth-Hitchcock
2. Age greater than 18 years old
3. Ability to provide written informed consent
Exclusion Criteria:
1. Inability to provide written informed consent
2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis
3. Current ongoing acute pancreatitis
4. Previously documented allergy to NSAID
5. Contra-indication to NSAID therapy (creatinine level >1.4 or active peptic ulcer
disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)
6. Pregnant or nursing mothers
We found this trial at
1
site
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
